Matches in Wikidata for { <http://www.wikidata.org/entity/Q91134650> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q91134650 description "articolo scientifico (pubblicato il 2019)" @default.
- Q91134650 description "artikull shkencor i botuar më 01 shkurt 2019" @default.
- Q91134650 description "artículu científicu espublizáu en febreru de 2019" @default.
- Q91134650 description "scientific article published on 01 February 2019" @default.
- Q91134650 description "wetenschappelijk artikel" @default.
- Q91134650 description "наукова стаття, опублікована в лютому 2019" @default.
- Q91134650 description "գիտական հոդված հրատարակված 2019 թվականի փետրվարի 1-ին" @default.
- Q91134650 name "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 name "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 name "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 type Item @default.
- Q91134650 label "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 label "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 label "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 prefLabel "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 prefLabel "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 prefLabel "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 P1433 Q91134650-32E6CE76-6F1F-4D44-A36A-DDDBE1CF3D42 @default.
- Q91134650 P1476 Q91134650-09D4A166-EB50-4C5F-A129-F2B10603739C @default.
- Q91134650 P2093 Q91134650-2FADEE93-7D0A-4F46-BAF3-BCCDFA575F54 @default.
- Q91134650 P2093 Q91134650-5D99F070-6A5E-4CE3-8653-4D2E8F9FB624 @default.
- Q91134650 P2093 Q91134650-6C30E587-4C08-4701-B17F-4A95D1051C0E @default.
- Q91134650 P2093 Q91134650-72369EAD-0776-478F-8DA1-95170E040CC6 @default.
- Q91134650 P2093 Q91134650-9161D54B-B965-44CA-B649-C15EEA13861B @default.
- Q91134650 P2093 Q91134650-A4E64258-22B9-43DB-9EFE-A9A516B45595 @default.
- Q91134650 P2093 Q91134650-A872EB1A-EC5D-431C-9C00-847B7ADB574C @default.
- Q91134650 P2093 Q91134650-AEE4EBE4-504E-4737-8174-9D1387370AF1 @default.
- Q91134650 P2093 Q91134650-BC971AF8-5082-4E4C-9B1F-7A7E85891F07 @default.
- Q91134650 P2093 Q91134650-BF5E31F8-757A-4EF2-B87E-4C9A6F2458CE @default.
- Q91134650 P304 Q91134650-74D33B33-8394-4875-9B9B-9179F1026917 @default.
- Q91134650 P31 Q91134650-115B9940-8973-4385-A71F-0DB1C0E1FB73 @default.
- Q91134650 P356 Q91134650-EB78C6F2-873B-4FB0-A17D-1483B19409D6 @default.
- Q91134650 P433 Q91134650-7BF219B1-0813-4598-981B-B03BF94DED16 @default.
- Q91134650 P478 Q91134650-98ECF235-A3F7-4179-AE01-D3B06642412E @default.
- Q91134650 P577 Q91134650-5FA715FC-07FD-42F3-97B5-0F1C4386961F @default.
- Q91134650 P698 Q91134650-B9B672FE-0711-4780-9F91-0962A690C2E5 @default.
- Q91134650 P921 Q91134650-991279E3-FD48-4B3C-83D8-745D5125503A @default.
- Q91134650 P932 Q91134650-D98B5088-3790-49B0-953C-D7F6B6C0E2E1 @default.
- Q91134650 P356 APT.15072 @default.
- Q91134650 P698 30663107 @default.
- Q91134650 P1433 Q4726656 @default.
- Q91134650 P1476 "Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study" @default.
- Q91134650 P2093 "Chinyu Su" @default.
- Q91134650 P2093 "Eric Maller" @default.
- Q91134650 P2093 "Gary Chan" @default.
- Q91134650 P2093 "Geert R D'Haens" @default.
- Q91134650 P2093 "Julián Panés" @default.
- Q91134650 P2093 "Linda Mele" @default.
- Q91134650 P2093 "Michele Moscariello" @default.
- Q91134650 P2093 "Peter D R Higgins" @default.
- Q91134650 P2093 "Wenjin Wang" @default.
- Q91134650 P2093 "Wojciech Niezychowski" @default.
- Q91134650 P304 "265-276" @default.
- Q91134650 P31 Q13442814 @default.
- Q91134650 P356 "10.1111/APT.15072" @default.
- Q91134650 P433 "3" @default.
- Q91134650 P478 "49" @default.
- Q91134650 P577 "2019-02-01T00:00:00Z" @default.
- Q91134650 P698 "30663107" @default.
- Q91134650 P921 Q1472 @default.
- Q91134650 P932 "6646954" @default.